Regulation of Antitumor Immunity by DC Subsets
Regulation of Antitumor Immunity by DC Subsets
批准号:
6773776
负责人:
YUKAI HE
金额:
$10.83万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-01 至 2007-03-31
中文摘要
K01导师职业发展奖的广泛目标是在肿瘤免疫学和树突状细胞(DC)生物学领域获得深入的研究培训和经验,最终目标是成为开发新型抗肿瘤治疗方式的独立研究员。该研究假设DC亚群在抗肿瘤免疫应答的启动和调节中起着非常重要的作用,其功能将受到肿瘤微环境和肿瘤衍生因子的影响。为了验证这一假说,我们将研究两个具体目标,即(1)髓系和淋巴系DC亚群的功能分析和比较;(2)肿瘤衍生因子对不同DC亚群抗原提呈功能的影响。这一建议的重要性在于,由于获得纯DC亚群的困难,以及从hFlex基因处理的小鼠中可以分离出高纯度的DC亚群,这是本实验室新开发的一种方法,因此对DC亚群的研究很少。这位候选人非常适合进行这项研究。何博士在医学、分子生物学和基因传递方面训练有素,这一点在他的17篇同行评议出版物和3篇提交的手稿中都有记载。该候选人致力于利用基因传递和分子生物学的知识和技术来研究DC生物学,并开发新的癌症治疗模式。这两个目标涉及现代免疫学和生物学的所有基本知识和技术。结合候选人已有的强大的分子生物学背景,以及他将通过拟议的研究接受的肿瘤免疫学和DC生物学的培训,他将处于非常有利的地位,通过利用分子生物学、肿瘤免疫学和DC生物学的知识和技术,在开发新的抗肿瘤方法领域成为一名独立的研究者。此次获奖的候选人所选择的环境非常出色。这位导师是小路易斯·D·法罗博士,他在肿瘤免疫学和DC生物学领域有很好的地位和资金。匹兹堡大学癌症研究所在Ronald Herberman博士、Theresa Whiteside博士和Olivera Finn博士的领导下,以其在肿瘤免疫学和DC应用方面的实力而闻名。威斯康星大学拥有最大的DC生物学和应用研究团队。在癌症生物学、肿瘤免疫学和DC生物学领域有三个久负盛名的系列研讨会和一个期刊俱乐部,部门和机构的资源都很好,知识环境也很好。此外,医学院的其他部门也提供了其他与癌症有关的研讨会。该研究所致力于通过提供所有资源的访问来全力支持候选人。候选人、研究方案和环境共同为该奖项提供了强有力的申请。
英文摘要
The broad objective of this K01 mentored career development award is to obtain in depth research training and experience in the field of tumor immunology and dendritic cell (DC) biology, with the ultimate goal of becoming an independent investigator for developing novel anti-tumor treatment modalities. The research proposal is based on the hypothesis that DC subsets play a very important role in the initiation and regulation of anti-tumor immune response and their function will be affected by the tumor microenvironment and tumor-derived factors. For testing this hypothesis, we will study two specific aims, i.e., (1) Functional analysis and comparison of myeloid and lymphoid DC subsets; (2) Influence of the tumor derived factors on the antigen presentation function of different subsets of DC. The importance of this proposal lies in the fact that DC subsets are scarcely studied due to the difficulty of obtaining pure DC subsets and on the ground that highly pure DC subsets can be isolated from hFlex gene treated mice, which is a newly developed approach in this lab. The candidate is highly suited to perform the research. Dr. He is well trained in medicine, molecular biology, and gene delivery as documented in his 17 peer-reviewed publications and three submitted manuscripts. The candidate is committed to using the knowledge and techniques of gene delivery and molecular biology to study the DC biology and develop novel cancer treatment modalities. The two aims involve all the basic knowledge and techniques of modern immunology and biology. Incorporating the strong background in molecular biology the candidate already has with the training in tumor immunology and DC biology as he will receive through the proposed research., he will be positioned very well in the path towards an independent investigator in the field of developing new anti-tumor approaches by harnessing the knowledge and techniques of molecular biology, tumor immunology and DC biology. The environment the candidate chosen for this award is outstanding. The mentor, Dr. Louis D. Falo Jr., is well established and well funded in the field of tumor immunology and DC biology. The University of Pittsburgh Cancer Institute (UPCI) is well known for its strength in tumor immunology and DC application under the leadership of Drs. Ronald Herberman, Theresa Whiteside and Olivera Finn. The UPCI has the largest research team on DC biology and application. The departmental and institutional resources are excellent and the intellectual environment is superb as there are three well-established seminar series in the area of cancer biology, tumor immunology and DC biology and one journal club. In addition, other cancer related seminars are also available from other departments in the school of medicine. The institute is committed to fully support the candidate by providing access to all of the resources. Together, the candidate, research proposal, and the environment provide a strong application for this award.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma
-
批准号:10532224
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2018
-
负责人:YUKAI HE
-
依托单位:
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma
-
批准号:10063495
-
项目类别:
-
资助金额:$2.99万
-
财政年份:2018
-
负责人:YUKAI HE
-
依托单位:
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma
-
批准号:10331001
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2018
-
负责人:YUKAI HE
-
依托单位:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
-
批准号:8693488
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2014
-
负责人:YUKAI HE
-
依托单位:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
-
批准号:9231438
-
项目类别:
-
资助金额:$32.06万
-
财政年份:2014
-
负责人:YUKAI HE
-
依托单位:
Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines
-
批准号:8827287
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2014
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:7488736
-
项目类别:
-
资助金额:$24.7万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:7257540
-
项目类别:
-
资助金额:$3.51万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:7759506
-
项目类别:
-
资助金额:$27.93万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:7356416
-
项目类别:
-
资助金额:$27.93万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:7575681
-
项目类别:
-
资助金额:$27.93万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization
-
批准号:8018491
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2007
-
负责人:YUKAI HE
-
依托单位:
Regulation of Antitumor Immunity by DC Subsets
-
批准号:6621423
-
项目类别:
-
资助金额:$10.52万
-
财政年份:2002
-
负责人:YUKAI HE
-
依托单位:
Regulation of Antitumor Immunity by DC Subsets
-
批准号:6434268
-
项目类别:
-
资助金额:$10.21万
-
财政年份:2002
-
负责人:YUKAI HE
-
依托单位:
Regulation of Antitumor Immunity by DC Subsets
-
批准号:6879131
-
项目类别:
-
资助金额:$11.16万
-
财政年份:2002
-
负责人:YUKAI HE
-
依托单位:
Regulation of Antitumor Immunity by DC Subsets
-
批准号:7064770
-
项目类别:
-
资助金额:$11.49万
-
财政年份:2002
-
负责人:YUKAI HE
-
依托单位:
海外基金